The Global Drug sales of Vyvanse stood at USD 3,806.84 Millions in 2022
The indicator recorded a historical growth (CAGR) of15% between 2019 to 2022 and is expected to decline by ...
GlobalData projects the indicator to decline at a CAGR of...
Lisdexamfetamine dimesylate (Vyvanse) is a psychostimulant agent. It is formulated as hard gelatin capsules and chewable tablets for oral route of administration.
Mechanism of Action
Lisdexamfetamine targets Sodium Dependent Dopamine Transporter (DA Transporter or DAT or Solute Carrier Family 6 Member 3 or SLC6A3); Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2). It functions via
Sodium Dependent Dopamine Transporter (DA Transporter or DAT or Solute Carrier Family 6 Member 3 or SLC6A3) Inhibitor; Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2) Inhibitor mechanism of action.
Vyvanse is a prodrug of dextroamphetamine. After oral administration, lisdexamfetamine is rapidly absorbed from the gastrointestinal tract and converted primarily in blood due to the hydrolytic activity of red blood cells to dextroamphetamine, which is responsible for the drug’s activity. Amphetamines are non-catecholamine sympathomimetic amines with CNS stimulant activity. Amphetamines block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space. These actions decrease motor restlessness, increase alertness, and diminish drowsiness and fatigue.
Vyvanse Overview
Vyvanse is marketed for the treatment of several indications in Central Nervous System therapy area.
Vyvanse is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and above and also indicated for the treatment of Eating Compulsion Disorder (ACT) in adults.
Vyvanse was first approved in 2007 and is sold globally including the US, the UK, Australia, Germany, and Japan by several pharma giants including Takeda Pharmaceutical Co Ltd, Shionogi & Co Ltd, and Shire Pharmaceuticals International UC. Vyvanse drug sales recorded a low-single digit Year on Year growth in 2022. Vyvanse drug sales include the historical sales that are derived from company financial reports, and consensus forecasts are calculated based on company-specific broker reports as well as GlobalData’s proprietary methodology.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward